Skip to content

D&A at other companies

Revvity logo
RevvityRVTY
$105.06M+7.8%
Azenta logo
AzentaAZTA
$14M+0.4%
Pacific Biosciences of California logo
Pacific Biosciences of CaliforniaPACB
$2.2M-57.1%
Personalis, Inc. logo
Personalis, Inc.PSNL
$2.37M-8.3%
Guardant Health logo
Guardant HealthGH
$9.44M-7.8%
Twist Bioscience Corporation logo
Twist Bioscience CorporationTWST
$6.41M+0.2%

Other financials

Income statement

See full
Revenue$1.2B+9.4%
Gross profit$770.0M+10.8%
Operating income$245.0M+14.5%
Net income$207.0M-11.9%
EPS (diluted)$1.35-9.4%

Balance sheet

See full
Cash & equivalents$1.0B+11.3%
Total debt$1.9B-7.3%
Total equity$2.8B+25.7%
Total assets$6.7B+9.2%

Cash flow

See full
Operating cash flow$201.0M-14.1%
CapEx$39.0M+30.0%
Free cash flow$162.0M-20.6%

Valuation

See full
Market cap$29.2B+69.7%
Enterprise value$30.1B+63.8%
P/E35.4×+21.7×
P/S6.5×+2.5×

Profitability

See full
Gross margin66.4%-0.2pp
Operating margin19.6%
Net margin18.4%-11.0pp
FCF margin20.7%-3.3pp

Returns & leverage

See full
Return on equity32.4%-35.7pp
Debt / equity0.7×-0.2×
Current ratio1.8×0.0×

Where this comes from

Reported directly by Illumina in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: Illumina’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Illumina's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Illumina's D&A?
Illumina (ILMN) reported D&A of $51M in Q1 2026.
How has Illumina's D&A changed year-over-year?
Illumina's D&A decreased by 1.9% year-over-year, from $52M to $51M.
What is the long-term trend for Illumina's D&A?
Over 4 years (2021 to 2025), Illumina's D&A has grown at a 3.6% compound annual growth rate (CAGR), from $176M to $203M.
What does D&A mean?
Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.